Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.

PD-1, PD-L1 inhibition effective against metastatic urothelial carcinoma

27 Nov 2019

Inhibitors against programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) provide comparable survival benefits in patients with platinum-resistant metastatic urothelial cancer (mUC), reports a recent meta-analysis.

Accessing the databases of Pubmed, Medline, Scopus and the Cochrane Register for Controlled trials, researchers retrieved phase I, II and III clinical trials that investigated the efficacy of anti-PD-1 or anti-PD-L1 antibodies for platinum-resistant mUC. A total of six clinical trials fulfilled eligibility criteria, comprising 1,315 patients treated with PD-1/PD-L1 and 736 who received chemotherapy.

The overall likelihood of survival in patients treated by PD-1/PD-L1 blockade at 6 months was 62 percent. This dropped to 42 percent at 12 months and to 31 percent at 18 months. The restricted mean survival times (RMST) at these timepoints were 4.8, 7.8 and 10 months, respectively.

Two of the included randomized trials compared PD-1 against PD-L1 and was included in a network meta-analysis. Researchers found that RMST at 18 months was statistically comparable between the two treatments (1 month, 95 percent confidence interval [CI], –0.5 to 2.3).

Using reconstructed data from three trials exploring PD-1 blockade (n=613) vs that of three other trials of PD-L1 blockade (n=702), researchers further confirmed the comparable benefits of both treatments. RMST at 12 months of follow-up was 7.8 months for both, which then increased to 10.1 and 10 months, respectively, at 18 months of follow-up.

“We acknowledge that there could be subtle differences among different drugs within the therapeutic subclasses of PD-1 and PD-L1 inhibitors, but we were unable to address such potential differences with the available data,” said researchers. This may have implications in the future design of clinical trials.

Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.